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Abstract: Tourette syndrome is a childhood-onset chronic tic disorder characterized by multiple 
motor and vocal tics and often accompanied by specific behavioral symptoms ranging from 
obsessionality to impulsivity. A considerable proportion of patients report significant impairment 
in health-related quality of life caused by the severity of their tics and behavioral symptoms 
and require medical intervention. The most commonly used medications are antidopaminergic 
agents, which have been consistently shown to be effective for tic control, but are also associ-
ated with poor tolerability because of their adverse effects. The newer antipsychotic medication 
aripiprazole is characterized by a unique mechanism of action (D2 partial agonism), and over 
the last decade has increasingly been used for the treatment of tics. We conducted a systematic 
literature review to assess the available evidence on the efficacy and safety of aripiprazole in 
pediatric patients with Tourette syndrome and other chronic tic disorders (age range: 4–18 years). 
Our search identified two randomized controlled trials (involving 60 and 61 participants) and 
ten open-label studies (involving between six and 81 participants). The majority of these stud-
ies used two validated clinician-rated instruments (Yale Global Tic Severity Scale and Clinical 
Global Impression scale) as primary outcome measures. The combined results from random-
ized controlled trials and open-label studies showed that aripiprazole is an effective, safe, and 
well-tolerated medication for the treatment of tics. Aripiprazole-related adverse effects (nausea, 
sedation, and weight gain) were less frequent compared to other antidopaminergic medications 
used for tic management and, when present, were mostly transient and mild. The reviewed studies 
were conducted on small samples and had relatively short follow-up periods, thus highlighting 
a need for further trials to assess the long-term use of aripiprazole in pediatric patients with 
Tourette syndrome and other chronic tic disorders with measurement of its efficacy using both 
clinician-rated and self-report scales.
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Background
Tourette syndrome (TS) is a chronic tic disorder characterized by the presence of 
both motor and vocal tics: repetitive movements and noises expressed as a result of 
specific sensory experiences or premonitory urges.1 The prevalence of TS worldwide 
is estimated to be up to 1% in school-age children and a male:female prevalence ratio 
of 3–4:1 has been consistently documented.2 The average age of tic onset is reported 
to be 6–7 years and peak severity is usually reached by early teenage years.3–5 The 
other chronic tic disorders (chronic motor or vocal tic disorder) follow a similar neu-
rodevelopmental trajectory, often with less severe symptoms than TS. In a significant 
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proportion of patients, tics improve and, in some cases, 
disappear by adulthood,6,7 although the characteristic urges 
are reported by the vast majority of adult patients with per-
sisting symptoms.8,9 TS is associated with neuropsychiatric 
comorbidities in ~90% of patients.2,3,10 The most common 
comorbid conditions are obsessive–compulsive disorder11 
and attention-deficit and hyperactivity disorder,12 which have 
been shown to significantly affect health-related quality of 
life,13 as well as impulse control disorders.14,15
Although the exact neurobiological mechanisms under-
lying TS and other chronic tic disorders remain unclear, 
there is converging evidence on the role of disruption to 
neurotransmission within the cortico-striato-thalamo-cortical 
pathways.6,16 The pathophysiological processes are thought 
to involve dysregulation of dopaminergic neurotransmis-
sion; however, both histaminergic17,18 and noradrenergic19,20 
pathways have also been proposed to be involved. These 
neurochemical changes have consistently been associated 
with genetic susceptibility, although no single causative gene 
defect has been identified.21,22 It is possible that the genetic 
heterogeneity which characterizes TS reflects the heterogene-
ity of the clinical phenotypes.
Treatment approaches to TS and other chronic tic dis-
orders show a considerable variability, depending on the 
severity and complexity of the clinical picture. In some 
cases, simple reassurance and psychoeducation are the only 
required interventions.23 In more severe cases, pharmaco-
logical therapy or behavioral interventions, such as habit 
reversal therapy, are often indicated.24,25 Furthermore, over 
the last 15 years, there have been several reports of patients 
with severe and treatment-refractory TS who underwent the 
neurosurgical procedure of deep brain stimulation in order 
to control their symptoms.26
The pharmacological treatment of TS and other chronic tic 
disorders encompasses different drug classes and recommen-
dations are often based on the findings of open-label studies.27 
The most commonly used medications are  antidopaminergic 
agents (neuroleptics or atypical antipsychotics),28,29 which are 
associated with known adverse effects.30 Other medications 
used include alpha-2 adrenoreceptor agonists, such as cloni-
dine and guanfacine.31 Serotonergic medications are helpful 
for obsessive–compulsive disorder symptoms, whereas 
central nervous system stimulants, such as methylphenidate, 
can be used for the treatment of comorbid attention-deficit 
and hyperactivity disorder.
Over the last decade, aripiprazole has increasingly been 
used for the treatment of children and adolescents with TS 
and other chronic tic disorders. Aripiprazole is an atypi-
cal antipsychotic agent licensed for use in the treatment of 
schizophrenia and mania in bipolar affective disorder.32,33 The 
mechanism of action of aripiprazole appears to be pharmaco-
logically distinct from that of other atypical antipsychotics. 
This medication was initially reported to be a high-affinity D2 
dopamine receptor partial agonist,34,35 although more recent 
pharmacological profiling studies have indicated a more com-
plex mechanism of action.36 Aripiprazole appears to display 
functionally significant interactions at a large number of amine 
G-protein coupled receptors, including D2, D3, and D4 dopa-
mine receptors, as well as at least six subtypes of serotonin 
receptors. The mode of action of aripiprazole at the level of 
the different receptors appears to be variable, with studies 
showing evidence for action as a full agonist, partial agonist, 
inverse agonist, and antagonist, depending on the receptor 
involved. The most frequently demonstrated mechanism is 
partial agonism at the level of dopaminergic and serotonergic 
receptors. In consideration of the rapidly expanding literature 
on the usefulness of aripiprazole in children and adolescents 
with TS, we set out to conduct a systematic review focusing 
on both safety and efficacy and encompassing randomized 
controlled trials and open-label studies in pediatric patients 
with TS and other chronic tic disorders.
Methods
This article reviews the available evidence on the efficacy 
and safety of aripiprazole in pediatric patients with TS and 
other chronic tic disorders. We conducted a systematic 
literature review on the PubMed database according to the 
methodological standards set out in the PRISMA (Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses) 
guidelines.37 Exclusion criteria covered studies published in 
languages other than English, studies involving adult popula-
tions only, studies assessing the use of aripiprazole in condi-
tions other than chronic tic disorders, and any molecular or 
animal studies. Case reports were individually assessed for 
relevance to our review. Studies in which the full data were 
not available (eg, conference abstracts) and other types of 
publications (eg, editorials, commentaries, letters to the edi-
tor) were excluded. Finally, reference lists from both retrieved 
studies and recent review articles were manually scanned to 
ensure that any additional relevant studies were not missed.
Our search identified two randomized controlled trials 
and ten open-label studies. The majority of these studies 
used Yale Global Tic Severity Scale (YGTSS) scores as their 
primary outcome measure for drug efficacy on tic control. 
The YGTSS is a clinician-rated scale of tic severity, which 
includes a number of different subscores.38,39 Patients are 
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scored on the severity of their motor and phonic tics sepa-
rately, and these scores can be combined to produce a total 
tic severity score out of 50. A higher score denotes a higher 
severity of tics. The total tic severity score, which takes into 
account the number, frequency, intensity, complexity, and 
interference of tics, is subsequently combined with a 0–50 
impairment score, measuring the effect of tics on a person’s 
overall daily functioning. The sum of the tic severity and 
impairment scores yields the global YGTSS score, with a 
maximum of 100 points. A few relevant studies also used 
the Clinical Global Impression (CGI) scale, a clinician-rated 
measure which assesses change in global daily functioning on 
a 7-point Likert-type scale.40 The CGI scale is not uniquely 
used in patients with tic disorders as it is frequently used 
across different neuropsychiatric and psychiatric conditions.41 
This instrument includes two subscores assessing the severity 
of symptoms and clinical improvement, respectively.
Randomized controlled trials
To date, two randomized controlled trials assessing the use 
of aripiprazole in young patients with TS and other chronic 
tic disorders have been published. The first trial was carried 
out between 2008 and 2010 by a research group based in 
the South Korea.42 Their study involved 61 patients (age 
range: 6–18 years) recruited across six centers. The authors 
assessed the efficacy of aripiprazole by measuring change in 
the total YGTSS scores and CGI-Improvement scores from 
baseline in 32 patients treated with aripiprazole compared 
to 29 patients who received placebo. The study took place 
over a 10-week period with YGTSS scores, CGI scores, and 
tolerability being assessed on a fortnightly basis. Aripipra-
zole was started at a dose of 2 mg/day with the possibility of 
gradually increasing it to 5, 10, 15, or 20 mg/day, according 
to tolerability and tic severity. The mean dose of aripipra-
zole across the study sample was 11 mg/day. At the end of 
the study period, mean YGTSS scores were decreased by 
15.0 points in the aripiprazole group and 9.6 points in the 
placebo group. This difference was statistically significant. 
Interestingly, the mean decrease in phonic tic severity was 
significantly larger in the aripiprazole group when compared 
to placebo. No difference was found in motor tic severity. 
Furthermore, the magnitude of the TS CGI severity score was 
significantly lower in the aripiprazole group compared to the 
placebo group. No patients in this study discontinued their 
treatment due to adverse effects; however, 75% of patients in 
the aripiprazole group reported adverse effects. Notably, over 
71% of patients in the placebo group also reported adverse 
effects. The most frequently reported effects included  nausea, 
 headache, sedation, somnolence, and nasopharyngitis. 
Both body weight and body mass index were significantly 
increased following aripiprazole treatment; however, no 
clinically significant changes were found on glucose and 
cholesterol measurement. The authors concluded that aripip-
razole is an efficacious treatment for the management of TS 
in children and adolescents that is generally well tolerated 
and safe in the short term.
In the second randomized controlled trial, which was 
published in 2013, aripiprazole was compared to risperi-
done in the treatment of children and adolescents with tic 
disorders.43 The study involved 60 patients between the ages 
of 6 and 18 years recruited from child psychiatry clinics 
affiliated with the Shiraz University of Medical Sciences 
in Iran. The study participants were randomly allocated to 
receiving either aripiprazole (n=31) or risperidone (n=29), 
and their YGTSS scores were assessed at baseline, week 4, 
and week 8. The initial dose of aripiprazole was 1.25 mg/day 
to be gradually increased up to 10 or 15 mg/day, depending 
on the child’s weight. The mean dose of aripiprazole used 
was 3.22 and 4.0 mg/day in the first and second month of 
the trial, respectively. At baseline, the mean tic severity 
scores did not differ between the two groups. At the end of 
the study, both aripiprazole and risperidone were found to 
significantly decrease the YGTSS total tic severity score, as 
well as the motor and phonic tic subscores. The authors found 
no significant differences in the decrease in scores between 
the aripiprazole and the risperidone groups. The most com-
mon adverse effects reported in the aripiprazole group were 
drowsiness (26%), increased appetite (26%), and decreased 
appetite (13%). One patient dropped out of the study due 
to severe sedation. The authors concluded that risperidone 
and aripiprazole are both effective in managing tics in chil-
dren and adolescents with TS. They suggested that further 
studies assessing tolerability and efficacy of long-term use 
of these medications should be undertaken.
Open-label studies
Our literature search identified ten open-label trials of aripip-
razole in young patients with chronic tic disorders, which are 
summarized in Table 1.
The first pilot study assessing the efficacy of aripiprazole 
in a pediatric population was published by a Korean group in 
2006.44 The authors treated six patients aged between 7 and 
17 years with aripiprazole at a mean dose of 10.9 mg and 
compared their YGTSS total severity scores at baseline with 
those after 8 weeks of treatment. In this study population, 
there was a 40.1% decrease in YGTSS scores at 8 weeks 
 
Pe
di
at
ric
 H
ea
lth
, M
ed
ici
ne
 a
nd
 T
he
ra
pe
ut
ics
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
4.
15
1.
16
.1
68
 o
n 
30
-J
an
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Pediatric Health, Medicine and Therapeutics 2016:7submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
60
Cox et al
Table 1 Summary of open-label studies on the use of aripiprazole in children and adolescents with tic disorders
Study Location Patients, n Protocol length, 
mean dose
YGTSS (decrease 
in total tic score), 
%
CGI Adverse effects Dropout due 
to adverse 
effects, %
Yoo et al44 South Korea 6 8 weeks, 10.9 mg/day 40.1 – Vomiting, sedation, 
weight gain
16.7
Yoo et al45 South Korea 24 8 weeks, 9.8 mg/day 52.8 79.2% much/very 
much improved 
Sedation, nausea, 
headache
25.0
Seo et al48 South Korea 15 12 weeks, 8.2 mg/day 55.7 – Nausea, sedation 6.7
Budman et al49 USA 37 12 weeks, 11.7 mg/day – 38.6% decrease in  
CGI severity score
Headaches, dizziness, 
nausea 
22.0
Lyon et al50 USA 11 10 weeks, 4.5 mg/day 40.8 91.0% much/very 
much improved,  
28.5% decrease in  
CGI severity score
Increased appetite, 
extrapyramidal, 
akathisia
9.1
Murphy et al51 USA 16 6 weeks, 3.3 mg/day 54.1 – Restlessness, 
irritability, nausea
0.0
Cui et al52 People’s 
Republic of 
China
72 8 weeks, 8.2 mg/day 50.3 53.9% decrease in  
CGI severity score
Nausea, sedation 2.8
Yoo et al46 South Korea 48 8 weeks, 10.6 mg/day 54.3 71.0% much/very 
much improved
Sedation, nausea, 
extrapyramidal 
16.1
Masi et al53 Italy 28 12 weeks, 10.0 mg/day 44.7 – Sedation, agitation, 
nausea 
0.0
Ho et al47 Taiwan 81 14 weeks, 2.8 mg/day 7.0* – Sedation, increased 
appetite, decreased 
appetite
11.1
Note: *Total YGTSS scores (including overall impairment). “–” indicates the data is not available.
Abbreviations: CGI, Clinical Global Impression; YGTSS, Yale Global Tic Severity Scale.
compared to baseline, with a decrease in the mean scores 
from 27.6 to 16.6. One patient withdrew from the study due 
to vomiting, but aripiprazole was otherwise well tolerated.
This research group subsequently published two further 
studies on the use of aripiprazole in children and adolescents 
with tic disorders. The first of these two studies was a larger 
open-label trial involving 24 patients with tic disorders aged 
7–18 years.45 The mean dose of aripiprazole administered to 
participants was 9.8 mg. There was an overall 52.8% reduc-
tion in YGTSS scores at 8 weeks, and 79.2% of the cohort 
was rated as having tic symptoms either much improved 
or very much improved on the CGI scale. In this study, six 
patients (25%) prematurely discontinued aripiprazole due to 
adverse effects. The second study compared aripiprazole to 
haloperidol in the treatment of TS over an 8-week period.46 
This study involved 48 patients aged 6–15 years, 31 of whom 
were prescribed aripiprazole at a mean dose of 10.6 mg. At 
8 weeks, there was a higher percentage decrease in total 
YGTSS scores in the haloperidol group compared to the 
aripiprazole group (63.4% vs 54.3%); however, the dropout 
rate due to adverse effects was higher in the haloperidol 
group. Interestingly, the proportion of patients deemed to 
be much improved or very much improved on the CGI scale 
was higher in the aripiprazole group (71.0%) compared to 
the haloperidol group (58.8%).
The largest open-label study to date was published in 
2013 by a research group based in Taiwan.47 These authors 
treated 81 patients with TS aged between 4 and 18 years with 
aripiprazole at a mean dose of 2.84 mg/day and recorded 
their YGTSS following 14 weeks of therapy. Nine patients 
withdrew due to adverse effects, 15 withdrew due to being 
symptom free for 2 weeks, and two withdrew as they expe-
rienced no significant beneficial effect. There was a mean 
reduction of 51% in motor tic scores, 67.1% in phonic tic 
scores, and 70% in total YGTSS scores. The authors con-
cluded that aripiprazole is a safe and generally well tolerated, 
effective medication for the treatment of tics in children. One 
of the main limitations of this study was the large percentage 
(65.4%) of patients with a diagnosis of transient tic disorder. 
This reduces the generalizability of the results to the wider 
patient with TS population, as the positive results may have 
been biased by the large number of patients who had transient 
and mild symptoms.
The combined results of the remaining six open-label 
studies48–53 confirmed the efficacy of aripiprazole in reducing 
both motor and vocal tic severity (Table 1). These  studies 
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were conducted on clinical cohorts of between eleven50 
and 7252 children and adolescents with tic disorders. Over 
study periods of 6–14 weeks, aripiprazole resulted in an 
overall reduction in tic severity in all cohorts for which 
data have been published. The mean dose of aripiprazole 
used in these open-label studies varied considerably from 
2.8 mg/day in the study by Ho et al47 to 11.7 mg/day in the 
study by  Budman et al,49 possibly accounting for some of 
the variability in effect size across studies. A few studies 
reported evidence for a larger improvement in vocal tics 
following administration of aripiprazole.47,51,53 Interestingly, 
this observation is in line with the findings of the randomized 
controlled trial by Yoo et al.42 Moreover, one study assessed 
aripiprazole in the setting of patients with comorbid TS and 
attention-deficit and hyperactivity disorder, and presented 
encouraging results for the role of this medication in manag-
ing comorbidities in addition to improving tics.53
The full picture emerging from the combined analysis of 
all the reviewed open-label studies (ten studies; 338 patients) 
indicates a decrease in YGTSS total tic severity scores of 
49.1% (combined data from eight studies) and a dropout due 
to adverse effects of 11.0% (combined data from ten studies).
Safety and tolerability issues
Aripiprazole appears to be a safe and generally well tolerated 
pharmacological option for young patients with TS and other 
chronic tic disorders. In the published randomized controlled 
trials and open-label studies, withdrawal rates varied between 
0% and 25%. The most frequently cited adverse effects 
included nausea, vomiting, fatigue, sedation, and weight 
gain, similar to what has been reported in the wider scientific 
literature on its use in child and adolescent psychiatry.54 The 
majority of adverse effects appear to be transient and settle 
within the first few weeks of treatment, although in a few 
cases increased appetite and weight gain can cause long-term 
problems. Not all the reviewed studies quantified weight gain 
in their patient cohorts, and there is wide variability in the 
reported findings. Some studies reported prevalence figures 
of significant weight gain as high as 87%,49 whereas other 
studies found no significant difference in body mass index 
after comparing pre- and post-aripiprazole body weight.48 
Moreover, although weight gain was frequently reported as 
a possible adverse effect of aripiprazole, it was not clinically 
significant in the majority of studies. Of note, the longest 
observational period for the reviewed studies was 14 weeks, 
thus suggesting that more long-term studies are required 
to assess the true impact of aripiprazole on body weight. 
Another adverse effect associated with atypical antipsychot-
ics is QTc prolongation on electrocardiogram. This is often 
an asymptomatic complication of drug treatment but can 
predispose to dangerous cardiac arrhythmias. The available 
evidence, including findings from studies conducted in young 
patients with TS,30 indicates that aripiprazole is characterized 
by an overall safer cardiological profile than other antidopa-
minergic agents.55,56 In the study by Cui et al52 on 72 Chinese 
children with tic disorders, 13 were found to have a longer 
QTc on electrocardiogram after aripiprazole treatment when 
compared to baseline; however, the QTc alteration did not 
meet age- and sex-related criteria to be defined as prolonged.
Patient-focused perspectives
Patient-focused perspectives are important components of 
the clinical assessment and outcome of patients with con-
ditions characterized by both physical and psychological 
symptoms. TS is a neuropsychiatric disorder with motor 
and behavioral aspects, which can have significant effects on 
patients’ health-related quality of life57 from an early age.58 
It is therefore important to consider the effects of pharma-
cological treatments on subjective aspects quality of life, in 
addition to tic frequency and severity. Both the YGTSS and 
CGI scales used in the reviewed studies of aripiprazole in 
young patients with tic disorder are clinician-rated instru-
ments. Although use of these instruments may provide more 
consistency among assessments, there is the possibility that 
opinions and feelings of the patients and their caregivers 
are overlooked. Medications, particularly antipsychotics, 
are associated with a range of adverse effects of different 
severity, which can have a negative impact on overall quality 
of life. In a recent qualitative study, young patients with TS 
and their parents were surveyed and interviewed to explore 
their perceptions of treatment.59 There was a strong percep-
tion among participants that health professionals had limited 
knowledge of the multifaceted clinical picture of TS and the 
available treatment options. The general consensus was that 
pharmacological treatment was beneficial in the management 
of TS; however, adverse effects were common. Interestingly, 
this study found that aripiprazole was viewed the most posi-
tively, with almost 70% of participants reporting it as being 
somewhat or very helpful, and only 25% reporting moderate 
or severe adverse effects. These figures were significantly 
better than those reported for the other seven frequently used 
medications for tic symptoms.
Conclusion
Taken together, the available evidence from both random-
ized controlled trials and open-label studies suggests that 
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 aripiprazole is an effective, safe, and well-tolerated medica-
tion for the treatment of TS and other tic disorders in pedi-
atric populations. These findings are in line with the results 
of three recently published meta-analyses, which suggested 
that aripiprazole appears to be a safe and promising therapy 
for children tic disorders,60,61 with similar efficacy to estab-
lished treatment options, such as the neuroleptics haloperidol 
and tiapride, and fewer extrapyramidal adverse effects than 
haloperidol.62 Large case series of adult patients with TS 
provide further support to these observations in terms of 
both safety63 and efficacy.64,65 Specifically, pharmacotherapy 
with aripiprazole has been consistently shown to result in 
significant reductions in tic severity as measured by the 
YGTSS. Likewise, the studies that used the CGI scale as 
an outcome measure found significant improvements in a 
large proportion of patients. Variable proportions of patients 
reported adverse effects from aripiprazole, most commonly 
nausea, sedation, and weight gain. These adverse effects 
appeared to be primarily transient and mild, and withdrawal 
rates from trials were low. Adverse effects also appeared to 
be fewer in frequency and milder in severity when compared 
to other medications used in the pharmacological treatment 
of tic symptoms.
In conclusion, the vast majority of studies considered 
in this review were of relatively low power due to small 
sample sizes. Of note, only two studies were deemed 
eligible to be included in a recent meta-analysis on the 
efficacy and safety of aripiprazole for patients of all ages 
with a diagnosis of TS,62 suggesting that further random-
ized controlled trials should be undertaken on larger patient 
cohorts. A multicenter randomized controlled trial on the 
efficacy and safety of once-weekly oral aripiprazole in 
children adolescents with TS was registered in 2011 (Clini-
calTrials.gov identifier: NCT01418339). Moreover, the 
patients recruited in the reviewed studies were followed-up 
for a relatively short period of time (up to 3–4 months) and 
the fact that most of the studies were performed in Asian 
countries might have possibly introduced a bias in their 
results. Further studies are needed to establish whether the 
beneficial effects and tolerability of aripiprazole persist 
with time and whether they can lead to symptom freedom. 
Future research should therefore be targeted at longer-term 
use of aripiprazole in pediatric patients with TS and other 
chronic tic disorders with measurement of its efficacy using 
both clinician-rated and self-report scales. This will help 
defining the role of aripiprazole in evidence-based practice 
guidelines on the treatment of children and adolescents 
with tic disorders.66
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